M. Weil

Genetics of Ustilago violacea. XV. Half-Tetrad Analysis, Single Selection, and Double Selection as Mapping Strategies

D. Kerrigan, E. Garber, M. Weil, 1983, Botanical Gazette.

Genetics of Ustilago violacea. XII. Half-Tetrad Analysis and Double Selection

E. Puscheck, S. Ward, E. Garber, 1982, Botanical Gazette.

PARP inhibitor treatment in ovarian and breast cancer.

A. Chen, Alice P Chen, Marcie K Weil, 2011, Current problems in cancer.

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile

L. Rubinstein, J. Doroshow, A. Chen, 2018, Investigational New Drugs.

Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).

L. Rubinstein, J. Doroshow, P. M. Williams, 2012 .

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Y. Pommier, L. Rubinstein, L. Jia, 2011, Cancer research.

BRCA Mutation and PARP Inhibitors

J. Doroshow, A. Chen, S. Kummar, 2013, Handbook of Therapeutic Biomarkers in Cancer.

Phase l study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors.

J. Doroshow, A. Chen, J. Trepel, 2012 .